Compare Danaher Corporation (DHR) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs 22nd Century Group Inc — how do they compare? Danaher Corporation trades at $201.52 (market cap $140.88B), while 22nd Century Group Inc trades at $4.27 (market cap $1.45M). The key difference: Danaher Corporation is far larger — about 97158.6× 22nd Century Group Inc's market cap, and Danaher Corporation pays a 0.8% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| DHR | XXII | |
|---|---|---|
Market Cap | $140.88B | $1.45M |
Sector | Health | Technology |
52-Week High | $242.05 | $1.47K |
52-Week Low | $161.91 | $3.90 |
Enterprise Value | $153.66B | -$6.78M |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
XXII trades at $4.10, down 3.07% today, with a bearish technical signal from moving averages. The company shows severe financial distress with a negative gross profit margin of -52.19% and net income margin of -65.76% for 2025. Recent news highlights expansion of VLN reduced-nicotine cigarettes in California and New York, aiming to capture market share. A 20:1 reverse stock split occurred on June 12, 2026, to adjust share structure.
The outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is 75% buy-rated. Investment opportunity hinges on successful commercialization of VLN products and FDA regulatory renewals. Key risks include execution challenges, intense competition, and reliance on financing to sustain operations amid negative cash flow from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
